Dynamic capsule restructuring by the main pneumococcal autolysin LytA in response to the epithelium

Nature Communications

Volumn 7, Issue , 2016, Pages

  Kietzman, Colin C ^a   Gao, Geli ^a   Mann, Beth ^a   Myers, Lance ^a   Tuomanen, Elaine I ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOLYSIN; BACTERIAL ENZYME; BACTERIAL PROTEIN; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; HYDROLASE; LYTA PROTEIN; UNCLASSIFIED DRUG; N ACETYLMURAMOYLALANINE AMIDASE;

ANTIBIOTICS; BACTERIUM; CARBOHYDRATE; CELLS AND CELL COMPONENTS; ENZYME; IMMUNE RESPONSE; RODENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC SENSITIVITY; ARTICLE; AUTOLYSIS; BACTERIAL CAPSULE; BACTERIAL CELL WALL; BACTERIAL GROWTH; BACTERIAL SHEDDING; BACTERIAL SURVIVAL; BACTERIAL VIABILITY; DISPERSION; EPITHELIUM CELL; FEMALE; LUNG INFECTION; MOUSE; NONHUMAN; PROTEIN FUNCTION; PROTEIN INTERACTION; SEROTYPE; STREPTOCOCCUS PNEUMONIAE; ANIMAL; BACTERIUM ADHERENCE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MICROBIOLOGY; MUTATION; PATHOLOGY; PHYSIOLOGY; PNEUMOCOCCAL INFECTION; STREPTOCOCCUS PNEUMONIA;

BACTERIA (MICROORGANISMS); MUS; STREPTOCOCCUS PNEUMONIAE;

ANIMALS; BACTERIAL ADHESION; BACTERIAL CAPSULES; BACTERIAL PROTEINS; EPITHELIAL CELLS; FEMALE; GENE EXPRESSION REGULATION, BACTERIAL; GENE EXPRESSION REGULATION, ENZYMOLOGIC; MICE; MUTATION; N-ACETYLMURAMOYL-L-ALANINE AMIDASE; PNEUMOCOCCAL INFECTIONS; PNEUMONIA, PNEUMOCOCCAL; STREPTOCOCCUS PNEUMONIAE;

EID: 84959377704     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms10859     Document Type: Article

References (57)

1. Sorensen, U. B., Henrichsen, J., Chen, H. C. & Szu, S. C. Covalent linkage between the capsular polysaccharide and the cell wall peptidoglycan of Streptococcus pneumoniae revealed by immunochemical methods. Microb. Pathog. 8, 325-334 (1990).
2. Hammerschmidt, S. et al. Illustration of pneumococcal polysaccharide capsule during adherence and invasion of epithelial cells. Infect. Immun. 73, 4653-4667 (2005).
3. Cundell, D. R., Weiser, J. N., Shen, J., Young, A. & Tuomanen, E. I. Relationship between colonial morphology and adherence of Streptococcus pneumoniae. Infect. Immun. 63, 757-761 (1995).
4. Goldman, M. J. et al. Human b-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis. Cell 88, 553-560 (1997).
5. McCray, P. B. & Bentley, L. Human airway epithelia express a beta-defensin. Am. J. Respir. Cell. Mol. Biol. 16, 343-349 (1997).
6. Bals, R., Wang, X., Zasloff, M. & Wilson, J. M. The peptide antibiotic LL-37/hCAP-18 is expressed in epithelia of the human lung where it has broad antimicrobial activity at the airway surface. Proc. Natl Acad. Sci. USA 95, 9541-9546 (1998).
7. Schaller-Bals, S., Schulze, A. & Bals, R. Increased levels of antimicrobial peptides in tracheal aspirates of newborn infants during infection. Am. J. Respir. Crit. Care Med. 165, 992-995 (2002).
8. Currie, S. M. et al. The human cathelicidin LL-37 has antiviral activity against respiratory syncytial virus. PLoS ONE 8, e73659 (2013).
9. Beaumont, P. E. et al. Cathelicidin host defence peptide augments clearance of pulmonary Pseudomonas aeruginosa infection by its influence on neutrophil function in vivo. PLoS ONE 9, e99029 (2014).
10. Cruse, G. et al. Human lung mast cells mediate pneumococcal cell death in response to activation by pneumolysin. J. Immunol. 184, 7108-7115 (2010).
11. Beiter, K. et al. The capsule sensitizes Streptococcus pneumoniae to alphadefensins human neutrophil proteins 1 to 3. Infect. Immun. 76, 3710-3716 (2008).
12. Llobet, E., Tomás, J. M. & Bengoechea, J. A. Capsule polysaccharide is a bacterial decoy for antimicrobial peptides. Microbiology 154, 3877-3886 (2008).
13. Lizcano, A., Chin, T., Sauer, K., Tuomanen, E. I. & Orihuela, C. J. Early biofilm formation on microtiter plates is not correlated with the invasive disease potential of Streptococcus pneumoniae. Microb. Pathog. 48, 124-130 (2010).
14. Chen, C. I. U., Schaller-Bals, S., Paul, K. P., Wahn, U. & Bals, R. b-defensins and LL-37 in bronchoalveolar lavage fluid of patients with cystic fibrosis. J. Cyst. Fibros. 3, 45-50 (2004).
15. Majchrzykiewicz, J. A., Kuipers, O. P. & Bijlsma, J. J. Generic and specific adaptive responses of Streptococcus pneumoniae to challenge with three distinct antimicrobial peptides, bacitracin, LL-37, and nisin. Antimicrob. Agents Chemother. 54, 440-451 (2010).
16. Tomasz, A. & Holtje, J. Murein hydrolases and the lytic and killing action of penicillin. Microbiology 1977, 209-215 (1977).
17. Bos, M. P. et al. Function of neisserial outer membrane phospholipase A in autolysis and assessment of its vaccine potential. Infect. Immun. 73, 2222-2231 (2005).
18. Henriques-Normark, B. & Tuomanen, E. I. The pneumococcus: epidemiology, microbiology, and pathogenesis. Cold Spring Harb. Perspect. Med. 3, 149-163 (2013).
19. Tomasz, A. & Waks, S. Mechanism of action of penicillin: triggering of the pneumococcal autolytic enzyme by inhibitors of cell wall synthesis. Proc. Natl Acad. Sci. USA 72, 4162-4166 (1975).
20. Lopez, R., Ronda, C. & Garcia, E. Autolysins are direct involved in the bactericidal effect caused by penicillin in wild type and in tolerant pneumococci. FEMS Microbiol. Lett. 54, 317-322 (1990).
21. Tomasz, A., McDonnell, M., Westphal, M. & Zanati, E. Coordinated incorporation of nascent peptidoglycan and teichoic acid into pneumococcal cell walls and conservation of peptidoglycan during growth. J. Biol. Chem. 250, 337-341 (1975).
22. Zasloff, M. Antimicrobial peptides of multicellular organisms. Nature 415, 389-395 (2002).
23. Wiedemann, I. et al. Specific binding of nisin to the peptidoglycan precursor lipid II combines pore formation and inhibition of cell wall biosynthesis for potent antibiotic activity. J. Biol. Chem. 276, 1772-1779 (2001).
24. Hu, Y., Helm, J. S., Chen, L., Ye, X. Y. & Walker, S. Ramoplanin inhibits bacterial transglycosylases by binding as a dimer to lipid II. J. Am. Chem. Soc. 125, 8736-8737 (2003).
25. Sass, V. et al. Human beta-defensin 3 inhibits cell wall biosynthesis in Staphylococci. Infect. Immun. 78, 2793-2800 (2010).
26. Breukink, E. et al. Use of the cell wall precursor lipid II by a pore-forming peptide antibiotic. Science 286, 2361-2364 (1999).
27. Cartee, R. T., Forsee, W. T. & Yother, J. Initiation and synthesis of the Streptococcus pneumoniae type 3 capsule on a phosphatidylglycerol membrane anchor. J. Bacteriol. 187, 4470-4479 (2005).
28. Sorensen, O., Bratt, T., Johnsen, A. H., Madsen, M. T. & Borregaard, N. The human antibacterial cathelicidin, hCAP-18, is bound to lipoproteins in plasma. J. Biol. Chem. 274, 22445-22451 (1999).
29. Kim, J. O. & Weiser, J. N. Association of intrastrain phase variation in quantity of capsular polysaccharide and teichoic acid with the virulence of Streptococcus pneumoniae. J. Infect. Dis. 177, 368-377 (1998).
30. Weiser, J. N., Markiewicz, Z., Tuomanen, E. I. & Wani, J. H. Relationship between phase variation in colony morphology, intrastrain variation in cell wall physiology, and nasopharyngeal colonization by Streptococcus pneumoniae. Infect. Immun. 64, 2240-2245 (1996).
31. Overweg, K. et al. Differential protein expression in phenotypic variants of Streptococcus pneumoniae. Infect. Immun. 68, 4604-4610 (2000).
32. Arai, J. et al. Streptococcus pneumoniae isolates from middle ear fluid and nasopharynx of children with acute otitis media exhibit phase variation. J. Clin. Microbiol. 49, 1646-1649 (2011).
33. Ogunniyi, A. D., Giammarinaro, P. & Paton, J. C. The genes encoding virulenceassociated proteins and the capsule of Streptococcus pneumoniae are upregulated and differentially expressed in vivo. Microbiology 148, 2045-2053 (2002).
34. Kasper, D. L. et al. Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine. J. Clin. Invest. 98, 2308-2314 (1996).
35. Shinefield, H. et al. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N. Engl. J. Med. 346, 491-496 (2002).
36. Toltzis, P. & Jacobs, M. R. The epidemiology of childhood pneumococcal disease in the United States in the era of conjugate vaccine use. Infect. Dis. Clin. North Am. 19, 629-645 (2005).
37. Croucher, N. J. et al. Rapid pneumococcal evolution in response to clinical interventions. Science 331, 430-434 (2011).
38. Zighelboim, S. & Tomasz, A. Multiple antibiotic resistance in South African strains of Streptococcus pneumoniae: mechanism of resistance to beta-lactam antibiotics. Rev. Infect. Dis. 3, 267-276 (1981).
39. Weiser, J. N., Austrian, R., Sreenivasan, P. K. & Masure, H. R. Phase variation in pneumococcal opacity: relationship between colonial morphology and nasopharyngeal colonization. Infect. Immun. 62, 2582-2589 (1994).
40. Moscoso, M. & Claverys, J.-P. Release of DNA into the medium by competent Streptococcus pneumoniae: kinetics, mechanism and stability of the liberated DNA. Mol. Microbiol. 54, 783-794 (2004).
41. Moscoso, M., García, E. & López, R. Biofilm formation by Streptococcus pneumoniae: role of choline, extracellular DNA, and capsular polysaccharide in microbial accretion. J. Bacteriol. 188, 7785-7795 (2006).
42. Ramos-Sevillano, E. et al. Pleiotropic effects of cell wall amidase LytA on Streptococcus pneumoniae sensitivity to the host immune response. Infect. Immun. 83, 591-603 (2015).
43. Tuomanen, E., Liu, H., Hengstler, B., Zak, O. & Tomasz, A. The induction of meningeal inflammation by components of the pneumococcal cell wall. J. Infect. Dis. 151, 859-868 (1985).
44. Tuomanen, E., Durack, D. T. & Tomasz, A. Antibiotic tolerance among clinical isolates of bacteria. Antimicrob. Agents Chemother. 30, 521-527 (1986).
45. Sourav, S. et al. Detection of pneumolysin and autolysin genes among antibiotic resistant Streptococcus pneumoniae in invasive infections. Indian. J. Med. Microbiol. 28, 34-39 (2010).
46. Olivares, A. et al. pep27 and lytA in vancomycin-tolerant pneumococci. J. Microbiol. Biotechnol. 21, 1345-1351 (2011).
47. Obregon, V. et al. Molecular peculiarities of the lytA gene isolated from clinical pneumococcal strains that are bile insoluble. J. Clin. Microbiol. 40, 2545-2554 (2002).
48. Mellroth, P. et al. LytA, major autolysin of Streptococcus pneumoniae, requires access to nascent peptidoglycan. J. Biol. Chem. 287, 11018-11029 (2012).
49. Rosch, J. W., Sublett, J., Gao, G., Wang, Y.-D. & Tuomanen, E. I. Calcium efflux is essential for bacterial survival in the eukaryotic host. Mol. Microbiol. 70, 435-444 (2008).
50. Horton, R. M., Hunt, H. D., Ho, S. N., Pullen, J. K. & Pease, L. R. Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension. Gene 77, 61-68 (1989).
51. Granok, A. B., Parsonage, D., Ross, R. P. & Caparon, M. G. The RofA binding site in streptococcus pyogenes is utilized in multiple transcriptional pathways. J. Bacteriol. 182, 1529-1540 (2000).
52. Sanz, J. M., Lopez, R. & Garcia, J. L. Structural requirements of choline derivatives for 'conversion' of pneumococcal amidase A new single-step procedure for purification of this autolysin. FEBS Lett. 232, 308-312 (1988).
53. Novak, R., Charpentier, E., Braun, J. S. & Tuomanen, E. Signal transduction by a death signal peptide: uncovering the mechanism of bacterial killing by penicillin. Mol. Cell 5, 49-57 (2000).
54. Rosch, J. W., Mann, B., Thornton, J., Sublett, J. & Tuomanen, E. Convergence of Regulatory Networks on the Pilus Locus of Streptococcus pneumoniae. Infect. Immun. 76, 3187-3196 (2008).
55. Mann, B. et al. Broadly protective protein-based pneumococcal vaccine composed of pneumolysin toxoid-CbpA peptide recombinant fusion protein. J. Infect. Dis. 209, 1116-1125 (2014).
56. Mann, B. et al. Multifunctional role of choline binding protein G in pneumococcal pathogenesis. Infect. Immun. 74, 821-829 (2006).
57. Francis, K. P. et al. Visualizing pneumococcal infections in the lungs of live mice using bioluminescent Streptococcus pneumoniae transformed with a novel Gram-positive lux transposon. Infect. Immun. 69, 3350-3358 (2001).